What serum zinc concentration should be targeted in an adult evaluated for chronic dysgeusia?

Target Serum Zinc Level for Chronic Dysgeusia

In an adult with chronic dysgeusia, target a serum zinc level above 70 μg/dL, with normalization to the laboratory reference range (typically 70-120 μg/dL) as the therapeutic goal.

Diagnostic Threshold and Monitoring

The 2022 ESPEN micronutrient guidelines establish that plasma zinc should be used to confirm clinical zinc deficiency and monitor adequacy of provision, with simultaneous measurement of CRP and albumin required for proper interpretation 1. This is critical because inflammatory states and hypoalbuminemia can artificially lower zinc levels independent of true deficiency.

Key Diagnostic Considerations:

• Zinc deficiency is defined as serum levels <70 μg/dL in most clinical contexts
• Measure baseline zinc along with CRP and albumin before initiating treatment
• Dysgeusia is an early manifestation of zinc deficiency, often appearing before other clinical signs 1

Treatment Targets and Timeline

When treating acquired zinc deficiency with dysgeusia, the evidence demonstrates:

Serum zinc normalization occurs progressively:

• Baseline levels typically 60-67 μg/dL in deficient patients 2, 3
• After 4 weeks: levels rise to approximately 100 μg/dL 2
• After 12 weeks: sustained levels of 100-101 μg/dL 2

Clinical improvement in dysgeusia lags behind biochemical correction:

• 18% improvement at 4 weeks
• 33% improvement at 8 weeks
• 42% improvement at 12 weeks 2

This temporal dissociation means you should continue zinc supplementation for at least 12 weeks even after normalizing serum levels, as taste recovery requires sustained adequate zinc status 4.

Treatment Dosing Based on Guidelines

The ESPEN guidelines provide clear dosing recommendations 1:

For acquired zinc deficiency (including dysgeusia):

• 0.5-1 mg/kg per day of elemental zinc orally for 3-4 months
• For a 70 kg adult, this translates to 35-70 mg elemental zinc daily
• Organic compounds (zinc gluconate, zinc acetate hydrate, zinc histidinate) show better tolerability than inorganic salts

Practical formulation considerations:

• Zinc acetate hydrate 50 mg elemental zinc daily is most effective 4
• This is superior to polaprezinc 34 mg daily, which showed slower improvement 4

Critical Pitfalls to Avoid

1. Don't stop treatment when zinc normalizes biochemically - Continue for full 3-4 months as taste recovery requires sustained repletion 1

2. Monitor copper levels - Chronic zinc supplementation can induce copper deficiency; check copper at baseline and during prolonged therapy 1

3. Account for inflammatory states - Elevated CRP lowers zinc levels independent of true deficiency; interpret results accordingly 1

4. Recognize that normal zinc doesn't exclude benefit - Studies show improvement in dysgeusia even in patients with baseline zinc >64 μg/dL, suggesting functional deficiency can occur at "normal" levels 5

5. ACE ratio may be more sensitive - The apo/holo-ACE activity ratio correlates better with treatment response than absolute zinc levels 5, though this is not routinely available

Monitoring Strategy

• Baseline: Zinc, CRP, albumin, copper
• 6 weeks: Zinc level to assess response
• 12 weeks: Zinc, copper, and clinical assessment of dysgeusia
• Continue treatment for full 3-4 months regardless of zinc normalization 1

The target is not just biochemical normalization but sustained adequate zinc status (>70 μg/dL, ideally 80-120 μg/dL) maintained throughout the treatment course to allow taste receptor regeneration and neurological recovery.